Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.